Nektar Therapeutics Webcast Conference Call with Immunology Specialists for Analysts at EULAR Transcript
Good day, ladies and gentlemen, and welcome to the 2019 EULAR Analyst Call. (Operator Instructions) As a reminder, this conference call may be recorded.
I would now like to introduce your host for today's conference, Ms. Jennifer Ruddock, Head of Investor Relations. Ma'am, you may begin.
Thank you, Crystal. Good morning, everyone, and thank you for joining us on today's analyst call to review data presented for NKTR-358 at the 2019 Annual European Congress of Rheumatology here in Madrid.
Before we start, I'll remind you that this presentation includes forward-looking statements regarding Nektar's drug candidate, NKTR-358, the timing of the start and conclusion of ongoing or planned clinical trial with partners and future availability of clinical trial data.
Actual results could differ materially and these statements are subject to important risks, which are detailed in Nektar's filings with the SEC, including our Form 10-Q filed in May 2019. Nektar undertakes
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |